Technology
Health
Medical

Atossa Genetics

$3.70
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.31 (-7.67%) Today
-$0.03 (-0.81%) After Hours

Why Robinhood?

You can buy or sell ATOS and other stocks, options, ETFs, and crypto commission-free!

About

Atossa Genetics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. Read More The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Employees
7
Headquarters
Seattle, Washington
Founded
2008
Market Cap
22.31M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
982.66K
High Today
$4.07
Low Today
$3.68
Open Price
$3.95
Volume
836.54K
52 Week High
$7.56
52 Week Low
$0.80

Collections

Technology
Health
Medical
Cancer Prevention
Pharmaceutical
Therapy
US
North America

News

Seeking AlphaMar 18

Atossa Genetics: Expect More Near-Term Positive Catalysts After Continued FDA Approval For One Patient

Atossa Genetics Inc. (ATOS) had a wild week last week after announcing that its proprietary oral Endoxifen was granted "Expanded Access" by the FDA for Post-Mastectomy Treatment for a U.S. Breast Cancer Patient. Third time was apparently a charm since the company announced it was originally given Expanded Access prior to the operation on December 3 and positive results were reported on February 7. Both updates resulted in a lot of volume being traded on the stock on those particular days but minimal price m...

450
Yahoo FinanceMar 18

Atossa Genetics Announces Receipt of $10 Million

Cash Proceeds from Exercise of Outstanding Warrants SEATTLE, March 18, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that on March 14 and 15, 2019, it received approximately $10 million from exercises of previously outstanding warrants. The warrants were issued by the Company in the rights offering completed May 30, 2018. As result of the ...

2,595
Seeking AlphaMar 15

Trade Alert: Long Atossa Genetics

However, the downside risk for this stock exists that Endoxifen may not achieve such positive results in future trials and/or individual case uses as was delivered recently in this initial reported instance.

1,341

Earnings

-$2.90
-$1.93
-$0.97
$0.00
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.63 per share
Actual
Expected Mar 22, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.